(Reuters) - Biogen Idec Inc's high profile new multiple sclerosis drug Tecfidera won European approval, the company said on Monday, opening the door for its launch in one of the world's largest ...

VANCOUVER — Fingolimod (Gilenya, Novartis) was better tolerated than dimethyl fumarate (Tecfidera, Biogen) in a 2-year comparison of the oral multiple sclerosis (MS) drugs. Patients receiving dimethyl ...

The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today. Dimethyl ...

LONDON, Nov 22 (Reuters) - Biogen Idec has won regulatory protection for its top-selling multiple sclerosis drug Tecfidera in Europe, paving the way for its launch in markets that could account for a ...

The closely-watched Cambridge company, which serves as a bellwether for the biotech sector as a whole, said this morning it took in a total of $2.6 billion in ...

Blockbuster status, an unofficial gold medal awarded to therapies racking up sales of $1 billion or more per year, is the holy grail for drug developers. Arguably, it's the chance to discover ...

Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug ...

Biogen BIIB reported third-quarter 2025 adjusted earnings per share (EPS) of $4.81, which beat the Zacks Consensus Estimate ...